Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 3/20 | 1.00 |
| ▸ | CETP | P11597 | 1/20 | 1.00 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.62 |
| ▸ | ACLY | P53396 | 3/20 | 0.62 |
| ▸ | IGF1R | P08069 | 2/20 | 0.59 |
| ▸ | SRC | P12931 | 2/20 | 0.59 |
| ▸ | AXL | P30530 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 2/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.59 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.59 |
| ▸ | MET | P08581 | 1/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | AKT1 | P31749 | 1/20 | 0.59 |
| ▸ | NEK2 | P51955 | 1/20 | 0.59 |
| ▸ | PLK1 | P53350 | 1/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.59 |
| ▸ | NEK6 | Q9HC98 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Avarol SCHEMBL10402772 | 1.00 | PTPN1 (1.00) | PTPN1PTGS2CETPPTPN6ACLY | |
| Avarol SCHEMBL21397196 | 1.00 | PTPN1 (1.00) | PTPN1PTGS2CETPPTPN6ACLY | |
| Avarol SCHEMBL31517137 | 1.00 | PTPN1 (1.00) | PTPN1PTGS2CETPPTPN6ACLY | |
| Avarol SCHEMBL9477102 | 0.99 | PTPN1 (0.98) | PTPN1PTGS2CETPPTPN6ACLY | |
| Avarol SCHEMBL9477704 | 0.97 | PTPN1 (0.94) | PTPN1PTGS2CETPPTPN6ACLY | |
| Avarol SCHEMBL9478364 | 0.89 | PTPN1 (0.80) | PTPN1PTGS2CETPPTPN6ACLY | |
| Avarone SCHEMBL5806251 | 0.88 | PTPN1 (0.77) | PTPN1PTGS2CETPPTPN6ACLY | |
| SCHEMBL31536047 | 0.84 | PTPN1 (1.00) | PTPN1PTGS2CETPPTPN6ACLY | |
| SCHEMBL31536088 | 0.81 | PTPN1 (0.68) | PTPN1PTGS2CETPPTPN6ACLY | |
| SCHEMBL9478317 | 0.80 | PTPN1 (0.78) | PTPN1PTGS2CETPPTPN6ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090160-A2 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20250122146-A1 | COMPOUNDS FOR REDUCING NEUROINFLAMMATION | THE SCRIPPS RESEARCH INSTITUTE | 2025-04-17 | — | — | US | claimed |
| CN-110678432-B | Composition for completely or partially replacing ball clay in ceramic and preparation method and application thereof | 活性矿物国际有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-110678432-A | Composition for completely or partially replacing ball clay in ceramic and preparation method and application thereof | 活性矿物国际有限公司 | 2020-01-10 | — | — | CN | claimed |
| JP-2011528275-A | — | — | 2011-11-17 | — | — | JP | claimed |
| EP-2313122-A1 | DRUG DELIVERY MEDICAL DEVICE | Micell Technologies, Inc. (US) | 2011-04-27 | — | — | EP | claimed |
| WO-2010009335-A1 | DRUG DELIVERY MEDICAL DEVICE | MICELL TECHNOLOGIES, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | claimed |
| EP-1919929-A4 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1919929-A2 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND Pharmaceuticals, Inc. (US) | 2008-05-14 | — | — | EP | claimed |
| EP-1391197-A1 | Process for preparation of compositions with a high content in avarol and their use | KliniPharm GmbH (DE) | 2004-02-25 | — | — | EP | claimed |
| US-6075057-A | INHIBITORS OF ALPHA-GLUCOSIDASE AND ALPHA-MANNOSIDASE; TREATMENT OF RETROVIRAL INFECTION-ASSOCIATED SYNDROMES, SUCH AS AIDS | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2000-06-13 | — | — | US | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| US-5082865-A | Avarol and its production and use as an antitumor agent (I) | MUELLER WERNER E G (DE) | 1992-01-21 | — | — | US | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| US-4946869-A | IN THE FORMS OF TABLETS, CAPSULES, ELIXIRS, SUPPOSITORIES OR STERILE INJECTABLE SOLUTIONS | MERZ AND CO. GMBH & CO. (DE) | 1990-08-07 | — | — | US | claimed |
| US-4939178-A | Use of avarol for the control of adult T-cell leukemia/lymphoma | MERZ + CO. GMBH & CO. (DE) | 1990-07-03 | — | — | US | claimed |
| US-4939177-A | Use of avarol for the control of AIDS and ARC | MERZ + CO. GMBH & CO. (DE) | 1990-07-03 | — | — | US | claimed |
| EP-0252305-A2 | Use of avarone and avarol and derivatives thereof for the preparation of a pharmaceutical composition for the control of adult T-cell leukemia/lymphoma | Merz & Co. GmbH & Co. (DE) | 1988-01-13 | — | — | EP | claimed |
| EP-0252304-A2 | Use of avarone and avarol and derivatives thereof for the preparation of a pharmaceutical composition for the control of AIDS and ARC | Merz & Co. GmbH & Co. (DE) | 1988-01-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122146-A1 | COMPOUNDS FOR REDUCING NEUROINFLAMMATION | HSF1, HSPA2, KEAP1 | PTPN1 3982/4885PTGS2 267/4885CETP 4053/4885 |
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | SI, SLC29A2, SLC29A1 | PTPN1 3857/4885PTGS2 2129/4885CETP 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.